Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient
Authors
Keywords
-
Journal
CYTOMETRY PART B-CLINICAL CYTOMETRY
Volume 90, Issue 1, Pages 14-20
Publisher
Wiley
Online
2015-07-04
DOI
10.1002/cyto.b.21273
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction
- (2015) A. C. Rawstron et al. BLOOD
- The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution
- (2015) N Puig et al. LEUKEMIA
- Minimal residual disease in multiple myeloma: bringing the bench to the bedside
- (2015) Sham Mailankody et al. Nature Reviews Clinical Oncology
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium
- (2014) Ola Landgren et al. AMERICAN JOURNAL OF HEMATOLOGY
- Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
- (2014) J. Martinez-Lopez et al. BLOOD
- The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma
- (2014) B. Paiva et al. HAEMATOLOGICA
- Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity
- (2013) A. Flanders et al. BLOOD
- Patient perceptions of second transplants in myeloma: impact on recruitment in the British Society of Blood and Marrow Transplantation/UK Myeloma Forum Myeloma X Relapse (Intensive) Trial
- (2013) Treen C. M. Morris et al. BRITISH JOURNAL OF HAEMATOLOGY
- Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma
- (2013) Prashant Kapoor et al. JOURNAL OF CLINICAL ONCOLOGY
- Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study
- (2013) Andy C. Rawstron et al. JOURNAL OF CLINICAL ONCOLOGY
- Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry
- (2013) N Puig et al. LEUKEMIA
- Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
- (2012) S. Kumar et al. BLOOD
- A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
- (2012) A. J. Jakubowiak et al. BLOOD
- Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial
- (2012) Sebastian Böttcher et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
- (2011) B. Paiva et al. BLOOD
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
- (2011) S. V. Rajkumar et al. BLOOD
- Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation
- (2011) E. Zamagni et al. BLOOD
- Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma
- (2011) Bruno Paiva et al. JOURNAL OF CLINICAL ONCOLOGY
- Monitoring Residual Myeloma
- (2010) Amanda D. Tatsas et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma
- (2009) C. E. Chee et al. BLOOD
- Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
- (2008) B. Paiva et al. BLOOD
- Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
- (2008) A. C. Rawstron et al. HAEMATOLOGICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started